Human Tuberculosis Vaccine Market, By Type (Live attenuated vaccine, Inactivated, and Others), By Age Group (Pediatrics and Adults), By Distribution Channel (Private and Public), By Geography (North America, Latin America, Asia Pacific, Europe, Middle Eas

Human Tuberculosis Vaccine Market, By Type (Live attenuated vaccine, Inactivated, and Others), By Age Group (Pediatrics and Adults), By Distribution Channel (Private and Public), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Tuberculosis remains one of the top 10 causes of death worldwide, despite being a curable and preventable disease. Currently, the only widely used TB vaccine is the Bacille Calmette-Guerin (BCG) vaccine, which provides limited protection and is only recommended for children. There is an urgent need for new, effective vaccines to control the global TB burden. Several candidate vaccines are in clinical trials, targeting different stages of the Mycobacterium tuberculosis lifecycle. Vaccines that provide lasting protection against pulmonary TB disease and transmission could be a game changer in the effort to eliminate this ancient pathogen.

Market Dynamics:

The global human tuberculosis vaccine market is primarily driven by the persistent burden of TB disease worldwide. On October 29, 2024, according to the WHO, a total of 1.25 million people died from tuberculosis (TB) in 2023. Worldwide, TB has probably returned to being the world's leading cause of death from a single infectious agent, following three years in which it was replaced by coronavirus disease (COVID-19). The need for improved diagnostics and vaccines has spurred heavy investments from global health organizations into TB vaccine R&D. Over 15 vaccine candidates are currently in clinical trials of different phases. However, high development costs and regulatory hurdles pose challenges. Scientists are exploring new technologies like mRNA platforms to improve the efficacy, safety, and ease of manufacture of tuberculosis vaccines. Asia Pacific is the largest market due to high TB prevalence in countries like India and China. Developing an effective vaccine could potentially curb disease transmission and generate substantial savings for overburdened healthcare systems.

Key Features of the Study:

• This report provides in-depth analysis of the global human tuberculosis vaccine market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global human tuberculosis vaccine market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include GSK plc., Serum Institute of India Pvt. Ltd., Valneva SE, Archivel Farma, BIOFABRI (Zendal), Japan BCG Laboratory, CSL Seqirus, GreenSignal Bio Pharma Private Limited (GSBPL), AJ Vaccines A/S, Taj Pharmaceuticals Ltd., Merck & Co., Inc., Bharat Biotech, Moderna, Inc., and BioNTech SE
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global human tuberculosis vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human tuberculosis vaccine market

Market Segmentation

• By Type Insights (Revenue, USD Mn, 2019 - 2031)
• Live attenuated vaccine
• Inactivated
• Others
• By Age Group Insights (Revenue, USD Mn, 2019 - 2031)
• Pediatrics
• Adults
• By Distribution Channel Insights (Revenue, USD Mn, 2019 - 2031)
• Private
• Public
• By Regional Insights (Revenue, USD Mn, 2019 - 2031)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• GSK plc.
• Serum Institute of India Pvt. Ltd.
• Valneva SE
• Archivel Farma
• BIOFABRI (Zendal)
• Japan BCG Laboratory
• CSL Seqirus
• GreenSignal Bio Pharma Private Limited (GSBPL)
• AJ Vaccines A/S
• Taj Pharmaceuticals Ltd.
• Merck & Co., Inc.
• Bharat Biotech
• Moderna, Inc.
• BioNTech SE